{"id":"benzbromarone-drug","safety":{"commonSideEffects":[{"rate":null,"effect":"Acute gout attack"},{"rate":null,"effect":"Hepatotoxicity"},{"rate":null,"effect":"Renal calculi"},{"rate":null,"effect":"Gastrointestinal disturbances"}]},"_chembl":{"chemblId":"CHEMBL388590","moleculeType":"Small molecule","molecularWeight":"424.09"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Benzbromarone is a uricosuric agent that acts on the apical membrane of proximal tubule cells in the kidney. By inhibiting the urate transporter 1 (URAT1), it prevents the reabsorption of filtered uric acid, promoting its elimination in urine. This mechanism effectively reduces serum uric acid concentrations, making it useful for managing hyperuricemia and gout.","oneSentence":"Benzbromarone inhibits renal urate reabsorption by blocking the urate transporter URAT1, thereby increasing urinary uric acid excretion and lowering serum uric acid levels.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-27T23:42:57.039Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Hyperuricemia and gout prophylaxis"}]},"trialDetails":[{"nctId":"NCT06966635","phase":"PHASE4","title":"Exploratory Study on the Treatment of Gout With Potassium Citrate Sustained-release Tablets","status":"RECRUITING","sponsor":"Huashan Hospital","startDate":"2024-04-10","conditions":"Hyperuricemia or Gout, Nephrolithiasis","enrollment":312},{"nctId":"NCT05504083","phase":"PHASE2","title":"Evaluate the Efficacy and Safety of D-0120 in Primary Hyperuricemia Patients","status":"COMPLETED","sponsor":"InventisBio Co., Ltd","startDate":"2022-09-28","conditions":"Hyperuricemia","enrollment":121},{"nctId":"NCT05210517","phase":"PHASE4","title":"SGLT2 Inhibition: Uric Acid Excretion Study","status":"COMPLETED","sponsor":"Amsterdam UMC, location VUmc","startDate":"2020-10-01","conditions":"Type 2 Diabetes","enrollment":10},{"nctId":"NCT03534037","phase":"PHASE4","title":"Urate Lowering Therapies and Left Ventricular Diastolic Dysfunction","status":"UNKNOWN","sponsor":"National Defense Medical Center, Taiwan","startDate":"2020-02-01","conditions":"Hyperuricemia, Metabolic Syndrome, Left Ventricular Diastolic Dysfunction","enrollment":120},{"nctId":"NCT03185793","phase":"PHASE2","title":"Dose-finding and Safety Study of SHR4640 in Subjects With Hyperuricemia","status":"COMPLETED","sponsor":"Jiangsu HengRui Medicine Co., Ltd.","startDate":"2017-07-20","conditions":"Hyperuricemia","enrollment":198},{"nctId":"NCT02338323","phase":"NA","title":"Compare the Renal Protective Effects of Febuxostat and Benzbromarone","status":"COMPLETED","sponsor":"Shanghai 10th People's Hospital","startDate":"2015-01","conditions":"Chronic Kidney Disease, Hyperuricemia, Abnormal Renal Function","enrollment":160},{"nctId":"NCT03100318","phase":"PHASE3","title":"Benzbromarone-Controlled, Double-Blind, Comparative Study of FYU-981 in Hyperuricemia With or Without Gout","status":"COMPLETED","sponsor":"Fuji Yakuhin Co., Ltd.","startDate":"2017-04-01","conditions":"Hyperuricemia With or Without Gout","enrollment":201},{"nctId":"NCT02790450","phase":"PHASE2","title":"Acute Effects of Benzbromaron on the Pulmonary Circulation","status":"COMPLETED","sponsor":"Medical University of Graz","startDate":"2015-10","conditions":"Idiopathic Pulmonary Arterial Hypertension","enrollment":10},{"nctId":"NCT02944214","phase":"NA","title":"Compare the Renal Protective Effects of Febuxostat and Benzbromarone in CKD Chinese Patients","status":"UNKNOWN","sponsor":"Shanghai 10th People's Hospital","startDate":"2016-10","conditions":"Chronic Kidney Disease, Hyperuricemia, Abnormal Renal Function","enrollment":800},{"nctId":"NCT02317861","phase":"PHASE1, PHASE2","title":"A PD/Safety Study of RDEA3170 in Combination With Febuxostat for Treating Gout or Asymptomatic Hyperuricemia Patients","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2014-12","conditions":"Gout and Asymptomatic Hyperuricemia","enrollment":110},{"nctId":"NCT00422318","phase":"PHASE4","title":"Treatment of Hyperuricemia in Patients With Heart Failure","status":"COMPLETED","sponsor":"Tottori University Hospital","startDate":"2004-01","conditions":"Heart Failure, Hyperuricemia","enrollment":""}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":264,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Benzbromarone (drug)","genericName":"Benzbromarone (drug)","companyName":"Tottori University Hospital","companyId":"tottori-university-hospital","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Benzbromarone inhibits renal urate reabsorption by blocking the urate transporter URAT1, thereby increasing urinary uric acid excretion and lowering serum uric acid levels. Used for Hyperuricemia and gout prophylaxis.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}